Published in Aliment Pharmacol Ther on July 22, 2015
The binding selectivity of vonoprazan (TAK-438) to the gastric H(+) ,K(+) -ATPase. Aliment Pharmacol Ther (2015) 1.96
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther (2015) 1.08
Vonoprazan: MarKed Competition for PPIs? Dig Dis Sci (2016) 0.75
Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. World J Gastrointest Endosc (2016) 0.75
Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep (2016) 0.75
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci (2017) 0.75
A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol (2017) 0.75
Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the (13)C-Urea Breath Test in Helicobacter pylori-Positive Patients. Dig Dis Sci (2017) 0.75
The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 2.64
Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion (1992) 1.95
Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol (2009) 1.89
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet (2005) 1.77
Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther (2010) 1.40
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol (2008) 1.27
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther (2011) 1.26
Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy (2003) 1.22
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol (2015) 1.19
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther (2015) 1.18
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther (2011) 1.16
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther (2005) 1.15
Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol (2009) 1.13
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol (2011) 1.12
A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol (2007) 1.10
Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther (2005) 1.05
The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther (2001) 1.03
Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther (2004) 1.00
Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol (2004) 0.99
Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem (2012) 0.96
Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep (2010) 0.96
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag (2007) 0.94
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther (2009) 0.93
Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med (2003) 0.89
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Rev Gastroenterol Disord (2008) 0.87
Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients. Intern Med (2013) 0.85
Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther (2012) 0.85
Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. Digestion (1992) 0.82
Neuroendocrine pathology of the stomach: the Parma contribution. Endocr Pathol (2014) 0.82
Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol (1999) 0.81
Mantel-Haenszel-type tests for testing equivalence or more than equivalence in comparative clinical trials. Biometrics (1994) 0.80
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther (2015) 2.46
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther (2015) 1.08